Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y

Core Insights - Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for Q3 2025, exceeding the Zacks Consensus Estimate of 51 cents and up from 57 cents in the same quarter last year [1][6] - Total revenues reached $148.4 million, reflecting a 15% year-over-year growth and surpassing the Zacks Consensus Estimate of $136 million [1][6] Revenue Breakdown - Firdapse sales amounted to $92.2 million, a 16% increase year-over-year, driven by strong demand and increased prescription rates [3][6] - Agamree generated revenues of $32.4 million, more than doubling year-over-year, and also exceeding estimates [5][6] - Fycompa reported net product revenues of $23.8 million, down 26% year-over-year due to generic competition, but still beating estimates [8][6] Financial Guidance - Following strong Q3 results, Catalyst Pharmaceuticals raised its 2025 revenue guidance to a range of $565 million to $585 million, up from the previous range of $545 million to $565 million [10][12] - Specific revenue expectations for Firdapse are between $355 million and $360 million, Agamree between $105 million and $115 million, and Fycompa between $100 million and $110 million [12] Strategic Developments - The company acquired exclusive rights to manufacture and supply Agamree in 2023, which was approved by the FDA for treating Duchenne Muscular Dystrophy [4][6] - Catalyst Pharmaceuticals settled its Firdapse patent litigation with Lupin, blocking generic competition until February 2035, which strengthens the long-term revenue outlook for Firdapse [14][15]